SELLAS Life Sciences Group, Inc. 8-K

What Happened SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K on June 25, 2026 reporting that on June 24, 2026 the Board approved (1) an amendment to CEO Dr. Angelos Stergiou’s employment agreement and (2) amended and restated severance and change of control letter agreements for John Burns (Senior VP & CFO) and Dr. Dragan Cicic (Senior VP & Chief Development Officer). The Board acted following a review with the company’s independent compensation consultant and a recommendation from the Compensation Committee.

Key Details

• Stergiou Amendment: change-in-control severance payments to Dr. Angelos Stergiou will be paid as a lump sum; all other terms unchanged.
• Burns and Cicic agreements (non-change-of-control termination): 9 months of base salary continuation, pro rata target bonus for year of termination paid over 9 months, and COBRA medical/dental premium reimbursement for up to 9 months.
• Burns and Cicic agreements (termination within Change of Control Period — 1 month before to 1 year after a change of control): lump sum of 15 months base salary, lump-sum target bonus for the year, COBRA reimbursement up to 18 months, and immediate vesting of all then-unvested equity awards.
• All severance payments are conditioned on the executive signing a separation and general release. The full agreements are filed as Exhibits 10.1–10.3 to the 8-K.

Why It Matters These amendments formalize severance protections and potential cash obligations for the company’s top executives, especially in the event of a change of control. For investors, this means that a future termination or a corporate transaction could trigger significant lump-sum payouts and accelerate equity vesting (potentially increasing near-term dilution). The filing does not report any current termination or change in control — it simply updates the contractual terms going forward.